当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
HEPLISAV-B, Hepatitis B Vaccine (Recombinant), Adjuvanted
申请企业
Dynavax Technologies Corporation
药品名称
HEPLISAV-B, Hepatitis B Vaccine (Recombinant), Adjuvanted
承诺描述
To establish a pregnancy registry for providing information on outcomes following pregnancy exposure to HEPLISAV-B. Data in this registry will be used to assess risks relevant to pregnancy, including pregnancy outcomes of pre-term births, major congenital malformations, spontaneous abortions, and still births. The registry will collect information on 250-300 pregnant women.